Inventor Search

KRISHNAN 09/923,023

```
=> d his

     (FILE 'HOME' ENTERED AT 17:07:31 ON 10 OCT 2003)

     FILE 'HCAPLUS' ENTERED AT 17:07:41 ON 10 OCT 2003
L1           75 S COLACO C?/AU
L2            6 S L1 AND GLYCOSID?
                SELECT RN 1 2 6 L2

     FILE 'REGISTRY' ENTERED AT 17:10:34 ON 10 OCT 2003
L3           69 S E1-69

     FILE 'HCAPLUS' ENTERED AT 17:11:03 ON 10 OCT 2003
L4            3 S L2 AND L3
```

3 cites w/ 69 cpds displayed

```
=> d ibib abs hitstr ind 1-3

L4   ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         1999:48730  HCAPLUS
DOCUMENT NUMBER:          130:129975
TITLE:                    Modified glycosides and compositions
                          comprised thereof for medical and other uses
INVENTOR(S):              Colaco, Camilo
PATENT ASSIGNEE(S):       Quadrant Holdings Cambridge Limited, UK
SOURCE:                   PCT Int. Appl., 39 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE          APPLICATION NO.  DATE
     ---------------   ----  --------      ---------------  --------
     WO 9901463         A2   19990114      WO 1998-GB1962   19980703
     WO 9901463         A3   19990325
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE,
             KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
             MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
             TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, ML, MR, NE, SN, TD, TG
     EP 994887          A2   20000426      EP 1998-932361   19980703
     EP 994887          B1   20021127
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2002510316      T2   20020402      JP 1999-506677   19980703
     AT 228528          E    20021215      AT 1998-932361   19980703
     ES 2187038         T3   20030516      ES 1998-932361   19980703
     US 2002009464      A1   20020124      US 2001-923023   20010806
PRIORITY APPLN. INFO.:                  US 1997-51727P   P  19970703
                                        WO 1998-GB1962   W  19980703
                                        US 1998-111925   A1 19980708
AB   Modified glycosides YnX (Y = saccharide subunit; X = C5-6 sugar
     alc.; n = 1-6; part or all of the OH groups in X and Y are derivatized as
     esters or ethers) are provided which can be used to form a variety of
     materials including biodegradable solid delivery systems and optically
     clear colored devices or coatings.  The solid delivery systems can be used
     for delivery and release of a variety of substances including lipids,
     proteins, peptides, peptidomimetics, hormones, saccharides, nucleic acids,
     and nucleoproteins, as well as viruses, bacteria, antigens, and haptens
     coupled to carriers; they can be in the form of tablets for oral
     administration, or in the form of powders, microspheres or implants for
     i.v., intradermal, transdermal, pulmonary, or other route of
     administration.  The modified glycosides may be processed to
     form a vitreous glass matrix having a substance, such as a therapeutic
```

agent, or an optically active dye incorporated therein. The vitreous glass matrix may be provided in a solid dosage form which is capable of releasing a therapeutic substance in situ at various controlled rates. Alternatively, a melt or soln. contg. modified **glycosides** and a dye can be used to produce optically clear colored coatings, plastic articles, and synthetic fibers. Thus, nonaacetylated derivs. of lactitol, palatinit, .alpha.-D-glucopyranosyl-(1.fwdarw.6)-sorbitol, and .alpha.-D-glucopyranosyl-(1.fwdarw.6)-mannitol with a range of m.p. values and glass transition temps. were produced by reaction of the polyols with Ac2O. Glasses produced by quenching melts of the acetylated polyols were good solvents for poorly water-sol. solutes such as Disperse Red 1; the solutes had little effect on the glass transition temp. and did not cause devitrification. Lactitol nonaacetate glasses contg. cyclosporin A and diltiazem-HCl showed different profiles of controlled release on immersion in saline soln.; the release rates were altered by addn. of Tween 20 to the soln.

IT **33286-22-5**, Diltiazem hydrochloride **59865-13-3**, Cyclosporin A
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modified **glycosides** and compns. comprised thereof for medical and other uses)

RN 33286-22-5 HCAPLUS

CN 1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, monohydrochloride, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RN 59865-13-3 HCAPLUS

CN Cyclosporin A (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



IT **9002-72-6**, Growth hormone **9004-10-8**, Insulin, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modified **glycosides** and compns. comprised thereof for medical and other uses)
RN 9002-72-6 HCAPLUS
CN Somatotropin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **37091-07-9P**, Lactitol nonaacetate **41897-24-9P**, Maltitol nonaacetate **41897-25-0P 219827-68-6P** **219827-69-7P**
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(modified **glycosides** and compns. comprised thereof for medical and other uses)
RN 37091-07-9 HCAPLUS
CN D-Glucitol, 4-O-(2,3,4,6-tetra-O-acetyl-.beta.-D-galactopyranosyl)-, pentaacetate (9CI) (CA INDEX NAME)



RN 41897-24-9 HCAPLUS
CN D-Glucitol, 4-O-(2,3,4,6-tetra-O-acetyl-.alpha.-D-glucopyranosyl)-, pentaacetate (9CI) (CA INDEX NAME)



RN 41897-25-0 HCAPLUS
CN D-Glucitol, 6-O-(2,3,4,6-tetra-O-acetyl-.alpha.-D-glucopyranosyl)-, pentaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 219827-68-6 HCAPLUS
CN D-Mannitol, 1-O-(2,3,4,6-tetra-O-acetyl-.alpha.-D-glucopyranosyl)-, pentaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 219827-69-7 HCAPLUS

CN D-Glucitol, 6-O-(2,3,4,6-tetra-O-acetyl-.alpha.-D-glucopyranosyl)-, pentaacetate, mixt. with 1-O-(2,3,4,6-tetra-O-acetyl-.alpha.-D-glucopyranosyl)[D-mannitol] pentaacetate (9CI) (CA INDEX NAME)

CM 1

CRN 219827-68-6
CMF C30 H42 O20

Absolute stereochemistry.



CM 2

CRN 41897-25-0
CMF C30 H42 O20

Absolute stereochemistry.



IT **50-70-4P**, D-Glucitol, biological studies **69-65-8P**, D-Mannitol **87-99-0P**, Xylitol **149-32-6P**, Erythritol **488-81-3P**, Ribitol **608-66-2P**, Galactitol
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(modified **glycosides** contg.; modified **glycosides** and compns. comprised thereof for medical and other uses)

RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 69-65-8 HCAPLUS
CN D-Mannitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 87-99-0 HCAPLUS
CN Xylitol (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 149-32-6 HCAPLUS
CN 1,2,3,4-Butanetetrol, (2R,3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 488-81-3 HCAPLUS
CN Ribitol (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 608-66-2 HCAPLUS
CN Galactitol (6CI, 8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **50-69-1P**, D-Ribose **50-99-7P**, D-Glucose, biological studies **57-48-7P**, D-Fructose, biological studies **58-86-6P**, D-Xylose, biological studies **59-23-4P**, D-Galactose, biological studies **65-42-9P**, Lyxose **147-81-9P**, Arabinose **3458-28-4P**, D-Mannose **5556-48-9P**, Ribulose **5987-68-8P**, Altrose **6038-51-3P**, Allose **19163-87-2P**, Gulose
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(modified polyol **glycosides** contg.; modified **glycosides** and compns. comprised thereof for medical and other uses)

RN 50-69-1 HCAPLUS
CN D-Ribose (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 50-99-7 HCAPLUS
CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-48-7 HCAPLUS
CN D-Fructose (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 58-86-6 HCAPLUS
CN D-Xylose (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 59-23-4 HCAPLUS
CN D-Galactose (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 65-42-9 HCAPLUS
CN Lyxose (6CI, 8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 147-81-9 HCAPLUS
CN Arabinose (8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 3458-28-4 HCAPLUS
CN D-Mannose (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 5556-48-9 HCAPLUS
CN erythro-2-Pentulose (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 5987-68-8 HCAPLUS
CN Altrose (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 6038-51-3 HCAPLUS
CN Allose (6CI, 8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 19163-87-2 HCAPLUS
CN Gulose (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **2872-52-8**, Disperse Red 1
RL: PRP (Properties)
(soly. in modified **glycoside** glass; modified **glycosides** and compns. comprised thereof for medical and other uses)
RN 2872-52-8 HCAPLUS
CN Ethanol, 2-[ethyl[4-[(4-nitrophenyl)azo]phenyl]amino]- (9CI) (CA INDEX NAME)



IC ICM C07H
CC 63-6 (Pharmaceuticals)
ST **glycoside** modified glass drug delivery; coating modified **glycoside** glass dye
IT Immunostimulants
(adjuvants; modified **glycosides** and compns. comprised thereof for medical and other uses)
IT Haptens
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates with carriers; modified **glycosides** and compns. comprised thereof for medical and other uses)
IT Drug delivery systems
(controlled-release, solid; modified **glycosides** and compns. comprised thereof for medical and other uses)
IT Drug delivery systems
(disks; modified **glycosides** and compns. comprised thereof for medical and other uses)
IT **Glycosides**
Oligosaccharides, biological studies
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(esters and ethers; modified **glycosides** and compns. comprised thereof for medical and other uses)
IT Drug delivery systems
(films; modified **glycosides** and compns. comprised thereof for medical and other uses)
IT Drug delivery systems
(implants; modified **glycosides** and compns. comprised thereof for medical and other uses)
IT Drug delivery systems
(lozenges; modified **glycosides** and compns. comprised thereof for medical and other uses)
IT Glass fibers, biological studies
RL: DEV (Device component use); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(microfibers; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Drug delivery systems
(microparticles; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Drug delivery systems
(microspheres; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Animal virus
Bacteria (Eubacteria)
Drug delivery systems
Dyes
Genetic vectors
Glass transition temperature
Needles (tools)
Optical filters
Peptidomimetics
Transparent materials
Vitreous materials
(modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Antigens
Carbohydrates, biological studies
Cytokines
Enzymes, biological studies
Growth factors, animal
Hormones, animal, biological studies
Interferons
Interleukins
Lipids, biological studies
Nucleic acids
Nucleoproteins
Peptides, biological studies
Proteins, general, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Isomaltooligosaccharides
Maltooligosaccharides
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(modified polyol **glycosides** contg.; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Acetylation
(of **glycosides**; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Quenching (cooling)
(of modified **glycoside** melts; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Solutions
(of modified **glycosides**, glass formation from; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Drug delivery systems
(particles; modified **glycosides** and compns. comprised thereof

for medical and other uses)

IT Alcohols, biological studies
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polyhydric, **glycosides**, esters and ethers; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Drug delivery systems
(powders; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Drug delivery systems
(spheres; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Drug delivery systems
(suppositories; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Drug delivery systems
(tablets; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Metals, uses
Plastics, uses
RL: DEV (Device component use); USES (Uses)
(transparent coatings on; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT Coating materials
(transparent; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT **33286-22-5**, Diltiazem hydrochloride **59865-13-3**, Cyclosporin A
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modified **glycosides** and compns. comprised thereof for medical and other uses)

IT **9002-72-6**, Growth hormone **9004-10-8**, Insulin, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(modified **glycosides** and compns. comprised thereof for medical and other uses)

IT **37091-07-9P**, Lactitol nonaacetate **41897-24-9P**, Maltitol nonaacetate **41897-25-0P** **219827-68-6P** **219827-69-7P**
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(modified **glycosides** and compns. comprised thereof for medical and other uses)

IT **50-70-4P**, D-Glucitol, biological studies **69-65-8P**, D-Mannitol **87-99-0P**, Xylitol **149-32-6P**, Erythritol **488-81-3P**, Ribitol **608-66-2P**, Galactitol
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(modified **glycosides** contg.; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT **50-69-1P**, D-Ribose **50-99-7P**, D-Glucose, biological studies **57-48-7P**, D-Fructose, biological studies **58-86-6P**, D-Xylose, biological studies **59-23-4P**, D-Galactose, biological studies **65-42-9P**, Lyxose **147-81-9P**, Arabinose **3458-28-4P**, D-Mannose **5556-48-9P**, Ribulose **5987-68-8P**, Altrose **6038-51-3P**, Allose **19163-87-2P**, Gulose
RL: DEV (Device component use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(modified polyol **glycosides** contg.; modified **glycosides** and compns. comprised thereof for medical and other uses)

IT **2872-52-8**, Disperse Red 1
RL: PRP (Properties)
(soly. in modified **glycoside** glass; modified **glycosides** and compns. comprised thereof for medical and other uses)

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1996:336393 HCAPLUS
DOCUMENT NUMBER: 125:19009
TITLE: Solid delivery systems for controlled release of molecules incorporated therein
INVENTOR(S): Roser, Bruce Joseph; **Colaco, Camilo**; Jerrow, Mohamed Abdel Zahra; Blair, Julian Alexander; Kampinga, Jaap; Wardell, James Lewis; Duffy, John Alistair
PATENT ASSIGNEE(S): Quadrant Holdings Cambridge Limited, UK
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9603978	A1	19960215	WO 1995-GB1861	19950804
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6290991	B1	20010918	US 1994-349029	19941202
CA 2197982	AA	19960215	CA 1995-2197982	19950804
AU 9531851	A1	19960304	AU 1995-31851	19950804
AU 688557	B2	19980312		
EP 773781	A1	19970521	EP 1995-927856	19950804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10503769	T2	19980407	JP 1995-506345	19950804
HU 77777	A2	19980828	HU 1998-694	19950804
CN 1204959	A	19990113	CN 1995-195496	19950804
EP 1138319	A2	20011004	EP 2001-116637	19950804
EP 1138319	A3	20030319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
EP 1138337	A2	20011004	EP 2001-116638	19950804
EP 1138337	A3	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV				
RU 2177785	C2	20020110	RU 1997-103529	19950804
EE 3593	B1	20020215	EE 1997-62	19950804
PL 184068	B1	20020830	PL 1995-318898	19950804
SK 283026	B6	20030204	SK 1997-277	19950804
FI 9700867	A	19970408	FI 1997-867	19970228
NO 9701688	A	19970411	NO 1997-1688	19970411
AU 9871864	A1	19980820	AU 1998-71864	19980612
AU 707605	B2	19990715		
US 6331310	B1	20011218	US 2000-628380	20000801
US 2001038858	A1	20011108	US 2001-755737	20010105
US 6586006	B2	20030701		
US 2002012687	A1	20020131	US 2001-945180	20010831
US 6565871	B2	20030520		

US 2003054040	A1	20030320	US 2002-280468		20021025
US 2003147961	A1	20030807	US 2003-376136		20030227
PRIORITY APPLN. INFO.:			GB 1994-15810	A	19940804
			US 1994-349029	A	19941202
			EP 1995-927856	A3	19950804
			WO 1995-GB1861	W	19950804
			US 1997-500877	B1	19970818
			US 2000-628380	A1	20000801
			US 2001-945180	A1	20010831

AB Solid dosage delivery systems suitable for delivery of bioactive materials s.c., intradermal, i.m., and i.v. are disclosed. The delivery systems comprise a vitreous vehicle, e.g. polyol, loaded with the guest substance and capable of releasing the guest substance in situ at various controlled rates. Microparticles were prepd. by spray drying a soln. of 0.39 M trehalose, 0.14 M calcium lactate and 0.5% MB9. This particles were coated by addn. of a satd. soln. of zinc palmitate in toluene and cooling at 60-30.degree.. The particles were then filtered under vacuum to remove excess zinc palmitate, washed with acetone, and air-dried. The resulting powder remained unwetted in water for .gtoreq. 3 days and released MB9 slowly into the water.

IT **50-99-7**, Glucose, biological studies **57-50-1**, biological studies **57-83-0**, Progesterone, biological studies **58-22-0**, Testosterone **63-42-3** **69-79-4** **99-20-7**, Trehalose **470-55-3** **512-69-6** **585-86-4**, Lactitol **585-88-6**, Maltitol **597-12-6**, Melezitose **604-68-2**, .alpha.-D-Glucose pentaacetate **604-69-3**, .beta.-D-Glucose pentaacetate **3616-19-1**, Cellobiose octaacetate **4618-18-2**, Lactulose **6424-12-0**, Raffinose undecaacetate **6556-12-3D**, Glucuronic acid, polymers **7208-47-1**, Sorbitol hexaacetate **9003-99-0**, Peroxidase **9004-10-8**, Insulin, biological studies **9004-54-0**, Dextran, biological studies **13718-94-0**, Isomaltulose **17273-84-6**, Aluminum hexanoate **17606-72-3**, Maltulose **20942-99-8** **25018-27-3**, Trehalose octaacetate **26023-30-3**, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] **26680-10-4**, Polylactide **26780-50-7**, Poly(glycolide-lactide) **27253-33-4**, Calcium neodecanoate **38954-67-5** **59865-13-3**, Cyclosporin a **64519-82-0**, Palatinit **66112-59-2**, Saf-1 **66594-14-7**, Quil a **102787-20-2** **177327-93-4** **177327-94-5** **177472-68-3**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release solid delivery systems comprising polyols)

RN 50-99-7 HCAPLUS
CN D-Glucose (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-50-1 HCAPLUS
CN .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-83-0 HCAPLUS
CN Pregn-4-ene-3,20-dione (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 58-22-0 HCAPLUS
CN Androst-4-en-3-one, 17-hydroxy-, (17.beta.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 63-42-3 HCAPLUS
CN D-Glucose, 4-O-.beta.-D-galactopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 69-79-4 HCAPLUS
CN D-Glucose, 4-O-.alpha.-D-glucopyranosyl- (6CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 99-20-7 HCAPLUS
CN .alpha.-D-Glucopyranoside, .alpha.-D-glucopyranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 470-55-3 HCAPLUS
CN .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.6)-O-.alpha.-D-galactopyranosyl-(1.fwdarw.6)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 512-69-6 HCAPLUS
CN .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.6)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 585-86-4 HCAPLUS
CN D-Glucitol, 4-O-.beta.-D-galactopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585-88-6 HCAPLUS
CN D-Glucitol, 4-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597-12-6 HCAPLUS
CN .alpha.-D-Glucopyranoside, O-.alpha.-D-glucopyranosyl-(1.fwdarw.3)-.beta.-D-fructofuranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604-68-2 HCAPLUS
CN .alpha.-D-Glucopyranose, pentaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 604-69-3 HCAPLUS
CN .beta.-D-Glucopyranose, pentaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 3616-19-1 HCAPLUS
CN D-Glucopyranose, 4-O-(2,3,4,6-tetra-O-acetyl-.beta.-D-glucopyranosyl)-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 4618-18-2 HCAPLUS
CN D-Fructose, 4-O-.beta.-D-galactopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 6424-12-0 HCAPLUS
CN .alpha.-D-Glucopyranoside, 1,3,4,6-tetra-O-acetyl-.beta.-D-fructofuranosyl O-2,3,4,6-tetra-O-acetyl-.alpha.-D-galactopyranosyl-(1.fwdarw.6)-, triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 6556-12-3 HCAPLUS
CN D-Glucuronic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 7208-47-1 HCAPLUS
CN D-Glucitol, hexaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 9003-99-0 HCAPLUS
CN Peroxidase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9004-54-0 HCAPLUS
CN Dextran (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 13718-94-0 HCAPLUS
CN D-Fructose, 6-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 17273-84-6 HCAPLUS
CN Hexanoic acid, aluminum salt (8CI, 9CI) (CA INDEX NAME)



●1/3 Al

RN 17606-72-3 HCAPLUS
CN D-Fructose, 4-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 20942-99-8 HCAPLUS
CN D-Mannitol, 1-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 25018-27-3 HCAPLUS
CN .alpha.-D-Glucopyranoside, 2,3,4,6-tetra-O-acetyl-.alpha.-D-glucopyranosyl, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 26023-30-3 HCAPLUS
CN Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] (8CI, 9CI) (CA INDEX NAME)



RN 26680-10-4 HCAPLUS
CN 1,4-Dioxane-2,5-dione, 3,6-dimethyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 95-96-5
CMF C6 H8 O4



RN 26780-50-7 HCAPLUS
CN 1,4-Dioxane-2,5-dione, 3,6-dimethyl-, polymer with 1,4-dioxane-2,5-dione (9CI) (CA INDEX NAME)

CM 1

CRN 502-97-6
CMF C4 H4 O4



CM 2

CRN 95-96-5
CMF C6 H8 O4



RN 27253-33-4 HCAPLUS
CN Neodecanoic acid, calcium salt (9CI) (CA INDEX NAME)



●1/2 Ca

RN 38954-67-5 HCAPLUS
CN .beta.-D-Glucopyranoside, octyl, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 59865-13-3 HCAPLUS
CN Cyclosporin A (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 64519-82-0 HCAPLUS
CN D-Glucitol, 6-O-.alpha.-D-glucopyranosyl-, mixt. with 1-O-.alpha.-D-glucopyranosyl-D-mannitol (9CI) (CA INDEX NAME)

CM 1

CRN 20942-99-8
CMF C12 H24 O11

Absolute stereochemistry.



CM 2

CRN 534-73-6
CMF C12 H24 O11

Absolute stereochemistry.



RN 66112-59-2 HCAPLUS
CN D-.alpha.-Glutamine, N-(N-acetylmuramoyl)-L-threonyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 66594-14-7 HCAPLUS
CN Quil-A (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 102787-20-2 HCAPLUS
CN .alpha.-D-Glucopyranoside, 1,3,4,6-tetrakis-O-(1-oxopropyl)-.beta.-D-fructofuranosyl, tetrapropanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177327-93-4 HCAPLUS
CN .alpha.-D-Glucopyranoside, 2,3,4,6-tetrakis-O-(1-oxopropyl)-.alpha.-D-glucopyranosyl, tetrapropanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 177327-94-5 HCAPLUS
CN .alpha.-D-Glucopyranoside, 1,3,4,6-tetrakis-O-(1-oxopropyl)-.beta.-D-fructofuranosyl O-2,3,4,6-tetrakis-O-(1-oxopropyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.6)-, tripropanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 177472-68-3 HCAPLUS
CN .beta.-D-Glucopyranose, 4-O-[2,3,4,6-tetrakis-O-(1-oxopropyl)-.beta.-D-glucopyranosyl]-, tetrapropanoate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K009-16
ICS A61K009-22
CC 63-6 (Pharmaceuticals)
ST controlled release solid delivery system polyol; microparticle MB9 lactate trehalose
IT Albumins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bovine; controlled-release solid delivery systems comprising polyols)
IT Animal cell
Bacteria

Measles
Molecules
Mumps
Poliomyelitis
Rubella
Shigella
Streptococcus pneumoniae
Tuberculosis
Vaccines
Virus
Yellow fever
(controlled-release solid delivery systems comprising polyols)

IT Analgesics
Animal growth regulators
Antibiotics
Antibodies
Anticoagulants and Antithrombotics
Antidepressants
Antiemetics
Antigens
Antihistaminics
Antihypertensives
Anxiolytics
Appetite depressants
Campylobacter pyloridis
Carbohydrates and Sugars, biological studies
Cardiovascular agents
Cholera
Cholinergic agonists
Cholinergic antagonists
Contraceptives
Dengue
Deoxyribonucleic acids
Diphtheria
Diuretics
Estrogens
Haptens
Hormones
Immunostimulants
Immunosuppressants
Inflammation inhibitors
Influenza
Interferons
Lipids, biological studies
Lymphokines and Cytokines
Mitogens
Muscle relaxants
Mycolic acids
Narcotic antagonists
Nitrates, biological studies
Nucleic acids
Nucleotides, biological studies
Oligosaccharides
Opioids
Organic matter
Peptides, biological studies
Phosphazene polymers
Phycoerythrins
Polyanhydrides
Polyesters, biological studies
Polysaccharides, biological studies
Proteins, biological studies
Ribonucleic acids
Saponins
Steroids, biological studies
Sulfates, biological studies
Tetanus

Tranquilizers and Neuroleptics
Virucides and Virustats
Whooping cough
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release solid delivery systems comprising polyols)

IT Pharmaceutical dosage forms
(fibers; controlled-release solid delivery systems comprising polyols)

IT Fissurella
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hemocyanins; controlled-release solid delivery systems comprising polyols)

IT Maillard reaction
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; controlled-release solid delivery systems comprising polyols)

IT **Glycosides**
Parkinsonism
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mono-reducing; controlled-release solid delivery systems comprising polyols)

IT Hepatitis
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(A, controlled-release solid delivery systems comprising polyols)

IT Hepatitis
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C, controlled-release solid delivery systems comprising polyols)

IT Hepatitis
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E, controlled-release solid delivery systems comprising polyols)

IT Virus, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Japanese encephalitis, controlled-release solid delivery systems comprising polyols)

IT Immunostimulants
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adjuvants, controlled-release solid delivery systems comprising polyols)

IT Immunostimulants
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adjuvants, Freund's, controlled-release solid delivery systems comprising polyols)

IT Carbohydrates and Sugars, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alditols, controlled-release solid delivery systems comprising polyols)

IT Inflammation inhibitors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiarthritics, controlled-release solid delivery systems comprising polyols)

IT Tranquilizers and Neuroleptics
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antipsychotics, controlled-release solid delivery systems comprising polyols)

IT Vasodilators
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cerebral, controlled-release solid delivery systems comprising polyols)

IT Therapeutics
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chemo-, controlled-release solid delivery systems comprising polyols)

IT Toxins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cholera, b subunit; controlled-release solid delivery systems comprising polyols)

IT Vasodilators
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coronary, controlled-release solid delivery systems comprising

polyols)
IT Oligosaccharides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(di-, controlled-release solid delivery systems comprising polyols)
IT Carboxylic acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(esters, controlled-release solid delivery systems comprising polyols)
IT Pharmaceutical dosage forms
(films, controlled-release solid delivery systems comprising polyols)
IT Neisseria meningitidis
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(group A, controlled-release solid delivery systems comprising polyols)
IT Neisseria meningitidis
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(group B, controlled-release solid delivery systems comprising polyols)
IT Neisseria meningitidis
(group C, controlled-release solid delivery systems comprising polyols)
IT Virus, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(herpes, controlled-release solid delivery systems comprising polyols)
IT Sulfates, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogen, controlled-release solid delivery systems comprising polyols)
IT Pharmaceutical dosage forms
(implants, controlled-release solid delivery systems comprising polyols)
IT Lymphokines and Cytokines
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukins, controlled-release solid delivery systems comprising polyols)
IT Glycophospholipids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipid A, monophosphates, controlled-release solid delivery systems comprising polyols)
IT Pharmaceutical dosage forms
(lozenges, controlled-release solid delivery systems comprising polyols)
IT Pharmaceutical dosage forms
(microparticles, controlled-release solid delivery systems comprising polyols)
IT Pharmaceutical dosage forms
(microspheres, controlled-release solid delivery systems comprising polyols)
IT Headache
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(migraine, agents for the treatment of; controlled-release solid delivery systems comprising polyols)
IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal, controlled-release solid delivery systems comprising polyols)
IT Glycopeptides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(muramic acid-contg., controlled-release solid delivery systems comprising polyols)
IT Surfactants
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonionic, controlled-release solid delivery systems comprising polyols)
IT Nucleotides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligo-, controlled-release solid delivery systems comprising polyols)
IT Polyethers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ortho ester group-contg., controlled-release solid delivery systems comprising polyols)

IT Virus, animal
(papilloma, controlled-release solid delivery systems comprising polyols)
IT Vasodilators
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peripheral, controlled-release solid delivery systems comprising polyols)
IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyhydric, controlled-release solid delivery systems comprising polyols)
IT Amino acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymers, controlled-release solid delivery systems comprising polyols)
IT Pharmaceutical dosage forms
(powders, controlled-release solid delivery systems comprising polyols)
IT Virus, animal
(respiratory syncytial, controlled-release solid delivery systems comprising polyols)
IT Virus, animal
(rota-, controlled-release solid delivery systems comprising polyols)
IT Carboxylic acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(salts, controlled-release solid delivery systems comprising polyols)
IT Pharmaceutical dosage forms
(solids, controlled-release, controlled-release solid delivery systems comprising polyols)
IT Pharmaceutical dosage forms
(spheres, controlled-release solid delivery systems comprising polyols)
IT Pharmaceutical dosage forms
(suppositories, controlled-release solid delivery systems comprising polyols)
IT Pharmaceutical dosage forms
(tablets, controlled-release solid delivery systems comprising polyols)
IT Oligosaccharides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tri-, controlled-release solid delivery systems comprising polyols)
IT Haemophilus influenzae
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type b, controlled-release solid delivery systems comprising polyols)
IT **50-99-7**, Glucose, biological studies **57-50-1**, biological studies **57-83-0**, Progesterone, biological studies **58-22-0**, Testosterone **63-42-3** **69-79-4** **99-20-7**, Trehalose **470-55-3** **512-69-6** **585-86-4**, Lactitol **585-88-6**, Maltitol **597-12-6**, Melezitose **604-68-2**, .alpha.-D-Glucose pentaacetate **604-69-3**, .beta.-D-Glucose pentaacetate **3616-19-1**, Cellobiose octaacetate **4618-18-2**, Lactulose **6424-12-0**, Raffinose undecaacetate **6556-12-3D**, Glucuronic acid, polymers **7208-47-1**, Sorbitol hexaacetate **9003-99-0**, Peroxidase **9004-10-8**, Insulin, biological studies **9004-54-0**, Dextran, biological studies **13718-94-0**, Isomaltulose **17273-84-6**, Aluminum hexanoate **17606-72-3**, Maltulose **20942-99-8** **25018-27-3**, Trehalose octaacetate **26023-30-3**, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] **26680-10-4**, Polylactide **26780-50-7**, Poly(glycolide-lactide) **27253-33-4**, Calcium neodecanoate **38954-67-5** **59865-13-3**, Cyclosporin a **64519-82-0**, Palatinit **66112-59-2**, Saf-1 **66594-14-7**, Quil a **102787-20-2** **177327-93-4** **177327-94-5** **177472-68-3**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release solid delivery systems comprising polyols)

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1992:124367 HCAPLUS
DOCUMENT NUMBER: 116:124367

TITLE: Stabilization of biological macromolecular substances and other organic compounds with nonreducing polyhydroxy **glycosides** or oligosaccharides
INVENTOR(S): Roser, Bruce Joseph; **Colaco, Camilo**
PATENT ASSIGNEE(S): Quadrant Holdings Cambridge Ltd., UK
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9118091	A1	19911128	WO 1991-GB759	19910514
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, PL, RO, SD, SE, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
AU 9178725	A1	19911210	AU 1991-78725	19910514
EP 541556	A1	19930519	EP 1991-909487	19910514
EP 541556	B1	19980916		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05508315	T2	19931125	JP 1991-509304	19910514
JP 3101320	B2	20001023		
AT 171209	E	19981015	AT 1991-909487	19910514
ES 2125237	T3	19990301	ES 1991-909487	19910514
US 5621094	A	19970415	US 1994-255565	19940608

PRIORITY APPLN. INFO.: GB 1990-10742 A 19900514
WO 1991-GB759 A 19910514
US 1992-965384 B1 19921214

AB (Bio)org. compds. are preserved in a dry state, at elevated temps., and/or under irradn. with nonreducing oligosaccharides or polyhydroxy **glycosides**. Restriction endonuclease PstI was dried at room temp. in the presence of trehalose then stored for 2 wks at 37.degree.. The enzyme retained 100% of its original activity after this treatment.

IT **13718-94-0**, Isomaltulose **64519-82-0**, Palatinit
50-70-4, Sorbitol, biological studies **57-50-1**, Sucrose, biological studies **69-65-8**, Mannitol **99-20-7**, Trehalose **470-55-3**, Stachyose **512-69-6**, Raffinose **534-73-6** **585-86-4**, Lactitol **585-88-6**, Maltitol **597-12-6**, Melezitose **4233-70-9**
RL: ANST (Analytical study)
(bioorg. compd. stabilization to drying and elevated temp. and irradn. with)

RN 13718-94-0 HCAPLUS
CN D-Fructose, 6-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 64519-82-0 HCAPLUS
CN D-Glucitol, 6-O-.alpha.-D-glucopyranosyl-, mixt. with 1-O-.alpha.-D-glucopyranosyl-D-mannitol (9CI) (CA INDEX NAME)

CM 1

CRN 20942-99-8
CMF C12 H24 O11

Absolute stereochemistry.



CM 2

CRN 534-73-6
CMF C12 H24 O11

Absolute stereochemistry.



RN 50-70-4 HCAPLUS
CN D-Glucitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 57-50-1 HCAPLUS
CN .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 69-65-8 HCAPLUS
CN D-Mannitol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 99-20-7 HCAPLUS
CN .alpha.-D-Glucopyranoside, .alpha.-D-glucopyranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 470-55-3 HCAPLUS
CN .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.6)-O-.alpha.-D-galactopyranosyl-(1.fwdarw.6)-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— OH

RN 512-69-6 HCAPLUS
CN .alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.6)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 534-73-6 HCAPLUS
CN D-Glucitol, 6-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585-86-4 HCAPLUS
CN D-Glucitol, 4-O-.beta.-D-galactopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 585-88-6 HCAPLUS
CN D-Glucitol, 4-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 597-12-6 HCAPLUS
CN .alpha.-D-Glucopyranoside, O-.alpha.-D-glucopyranosyl-(1.fwdarw.3)-.beta.-D-fructofuranosyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 4233-70-9 HCAPLUS
CN D-Mannose, 6-O-.alpha.-D-glucopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **9012-36-6P**, Agarose
RL: PREP (Preparation)
(gels, stabilization to drying of, nonreducing oligosaccharides and polyhydroxy **glycosides** in)
RN 9012-36-6 HCAPLUS
CN Agarose (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **9003-99-0D**, Peroxidase, fusion products with Ig F(ab)2 fragment
81295-32-1, Restriction endonuclease PstI
RL: ANST (Analytical study)
(stabilization to drying of, nonreducing oligosaccharides and polyhydroxy **glycosides** in)

RN 9003-99-0 HCAPLUS
CN Peroxidase (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 81295-32-1 HCAPLUS
CN Nuclease, restriction endodeoxyribo-, PstI (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IC ICM C12N009-96
ICS A61K047-26
CC 9-2 (Biochemical Methods)
ST bioorg compd preservation drying temp; irradn bioorg compd preservation; oligosaccharide nonreducing bioorg compd preservation; polyhydroxy **glycoside** nonreducing preservation biomol
IT Galactosides
Glycosides
Oligosaccharides
RL: ANST (Analytical study)
(nonreducing, bioorg. compd. stabilization to drying and elevated temp. and irradn. with)
IT Preservation
(of org. and bioorg. compds., to drying and elevated temp. and irradn., with nonreducing polyhydroxy **glycosides** and oligosaccharides)
IT Temperature effects, biological
(on org. and bioorg. compds., stabilization with nonreducing polyhydroxy **glycosides** and oligosaccharides in relation to.)
IT Drying
(stabilization of org. and bioorg. compds. to, with nonreducing polyhydroxy **glycosides** and oligosaccharides)
IT Organic compounds, miscellaneous
RL: MSC (Miscellaneous)
(stabilization of, to drying and elevated temp. and irradn., with nonreducing polyhydroxy **glycosides** and oligosaccharides)
IT Light stabilizers
(UV, nonreducing polyhydroxy **glycosides** and oligosaccharides as, for org. and bioorg. compds.)
IT Carbohydrates and Sugars, uses
RL: USES (Uses)
(alditols, nonreducing, **glycosides**, bioorg. compd. stabilization to drying and elevated temp. and irradn. with)
IT Organic compounds, miscellaneous
RL: MSC (Miscellaneous)
(biol., stabilization of, to drying and elevated temp. and irradn., with nonreducing polyhydroxy **glycosides** and oligosaccharides)
IT Oligosaccharides
RL: ANST (Analytical study)
(di-, nonreducing, bioorg. compd. stabilization to drying and elevated temp. and irradn. with)
IT Alcohols, uses
RL: USES (Uses)
(polyhydric, nonreducing, **glycosides**, bioorg. compd. stabilization to drying and elevated temp. and irradn. with)
IT Phycoerythrins
RL: ANST (Analytical study)
(R-, stabilization to drying of, nonreducing oligosaccharides and polyhydroxy **glycosides** in)
IT **13718-94-0**, Isomaltulose **64519-82-0**, Palatinit
50-70-4, Sorbitol, biological studies **57-50-1**, Sucrose, biological studies **69-65-8**, Mannitol **99-20-7**, Trehalose **470-55-3**, Stachyose **512-69-6**, Raffinose **534-73-6 585-86-4**, Lactitol **585-88-6**, Maltitol **597-12-6**, Melezitose **4233-70-9**
RL: ANST (Analytical study)
(bioorg. compd. stabilization to drying and elevated temp. and irradn. with)
IT **9012-36-6P**, Agarose
RL: PREP (Preparation)

(gels, stabilization to drying of, nonreducing oligosaccharides and polyhydroxy **glycosides** in)

IT **9003-99-0D**, Peroxidase, fusion products with Ig F(ab)2 fragment
81295-32-1, Restriction endonuclease PstI
RL: ANST (Analytical study)
(stabilization to drying of, nonreducing oligosaccharides and polyhydroxy **glycosides** in)